Wescott Financial Advisory Group LLC Takes $2.28 Million Position in Johnson & Johnson (NYSE:JNJ)

Wescott Financial Advisory Group LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 13,229 shares of the company’s stock, valued at approximately $2,278,000. Johnson & Johnson makes up approximately 1.3% of Wescott Financial Advisory Group LLC’s investment portfolio, making the stock its 9th biggest holding.

Several other large investors have also recently modified their holdings of JNJ. Nottingham Advisors Inc. increased its position in Johnson & Johnson by 7.5% during the 2nd quarter. Nottingham Advisors Inc. now owns 5,896 shares of the company’s stock worth $971,000 after purchasing an additional 413 shares in the last quarter. Marks Group Wealth Management Inc increased its position in Johnson & Johnson by 3.4% during the 2nd quarter. Marks Group Wealth Management Inc now owns 7,750 shares of the company’s stock worth $1,271,000 after purchasing an additional 257 shares in the last quarter. Coastal Bridge Advisors LLC increased its position in Johnson & Johnson by 14.8% during the 2nd quarter. Coastal Bridge Advisors LLC now owns 18,553 shares of the company’s stock worth $3,056,000 after purchasing an additional 2,389 shares in the last quarter. BerganKDV Wealth Management LLC increased its position in Johnson & Johnson by 4.2% during the 2nd quarter. BerganKDV Wealth Management LLC now owns 36,503 shares of the company’s stock worth $6,013,000 after purchasing an additional 1,478 shares in the last quarter. Finally, Smith Anglin Financial LLC grew its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. Smith Anglin Financial LLC now owns 5,295 shares of the company’s stock worth $872,000 after acquiring an additional 133 shares during the last quarter. Institutional investors own 67.29% of the company’s stock.

Shares of Johnson & Johnson stock traded up $0.78 during trading on Wednesday, reaching $165.58. 250,651 shares of the company traded hands, compared to its average volume of 7,095,660. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.39 and a quick ratio of 1.13. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $179.92. The company has a 50 day moving average price of $172.45 and a 200-day moving average price of $167.19. The firm has a market capitalization of $435.89 billion, a PE ratio of 24.78, a P/E/G ratio of 2.23 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.29 by $0.19. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The company had revenue of $23.31 billion for the quarter, compared to the consensus estimate of $22.54 billion. During the same quarter in the previous year, the company earned $1.67 EPS. Johnson & Johnson’s quarterly revenue was up 27.1% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 9.65 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were given a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s payout ratio is presently 52.80%.

A number of equities research analysts have weighed in on JNJ shares. Credit Suisse Group set a $193.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Finally, Morgan Stanley lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price on the stock. in a report on Tuesday, September 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $190.38.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading: Initial Coin Offering (ICO)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.